June 28, 2017 1:35 PM ET

Pharmaceuticals

Company Overview of Janssen R&D Ireland

Company Overview

Janssen R&D Ireland operates as a pharmaceutical research and development company. It focuses on the development of HIV/AIDS compounds and drugs for other infectious diseases. The company develops a global access program to facilitate access to its antiretrovirals for patients living with HIV/AIDS. Its global access program for PREZISTA includes access pricing, registration, and medical education for use and voluntary licensing. The company was formerly known as Tibotec Pharmaceuticals Limited and changed its name to Janssen R&D Ireland on February, 2012. The company was founded in 1994 and is based in Cork, Ireland with an additional office in Yardley, Pennsylvania; operating affiliates in ...

Eastgate Village

Eastgate

Little Island

Cork,  

Ireland

Founded in 1994

Phone:

353 21 4673500

Fax:

353 21 4673520

Key Executives for Janssen R&D Ireland

Compensation as of Fiscal Year 2016.

Janssen R&D Ireland Key Developments

Janssen Announces Encouraging Data from Phase III Psoriatic Arthritis Study

Janssen R&D, LLC has announced results from the pivotal Phase III GO-VIBRANT study that showed the significant efficacy of the intravenously administered anti-tumor necrosis factor (TNF)-alpha therapy SIMPONI ARIA (golimumab) in the treatment of active psoriatic arthritis. In GO-VIBRANT, 75.1% of patients with active psoriatic arthritis receiving SIMPONI ARIA 2 mg/kg achieved at least a 20% improvement in arthritis signs and symptoms as measured by the American College of Rheumatology (ACR20) at week 14, the study's primary endpoint, compared with 21.8% of patients receiving placebo (P < 0.001). SIMPONI ARIA also showed significant improvement across all secondary endpoints evaluating improvements in skin symptoms, joint damage and health-related quality of life measures.Data from GO-VIBRANT are being presented for the first time at the Annual European Congress of Rheumatology (EULAR) 2017. SIMPONI ARIA is currently under review by the FDA for the treatment of adults with active psoriatic arthritis and the treatment of adults with ankylosing spondylitis. SIMPONI ARIA is approved in the US for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate.

Similar Private Companies By Industry

Company Name Region
ADAPT Pharma, Inc. Europe
Artelo Biosciences, Inc. Europe
Bimeda Holdings PLC Europe
Carrick Therapeutics, Ltd. Europe
Celtic Catalysts Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Janssen R&D Ireland, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.